Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content
SpringerLink
Log in

The Utility of PET/CT in the Management of Patients With Colorectal Liver Metastases Undergoing Laparascopic Radiofrequency Thermal Ablation

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

There are scant data in the literature about the use of PET in the management of patients undergoing RFA of colorectal liver metastases (CLM). The aim of this study is to look at the use of PET versus contrast-enhanced CT (ce CT) scans on the initial assessment and follow-up of patients with CLM undergoing laparoscopic RFA.

Methods

The patients who had PET scans pre-RFA and post-RFA were identified from a prospective IRB-approved database within a 14-year period. The findings of PET scans were compared to those of ce CT. Kaplan–Meier survival, Cox proportional hazards, t test, and chi square analyses were performed.

Results

A total of 134 patients had PET scans prior to laparoscopic RFA and 104 (28%) had PET/CT scans in follow-up, with comparison ce CT done within a month in 82 patients. In follow-up, PET/CT findings were equivalent to ce CT in 55 patients (67%), superior in 22 (27%), and inferior in 5 (6%). Pre-RFA or post-RFA PET imaging did not affect overall survival. The patients in whom the benefit of PET/CT was most were those with multiple bilobar tumors.

Conclusions

Although, there was no survival benefit, PET/CT was superior to ce CT in demonstrating recurrence after RFA in about a quarter of the patients with CLM. The patients who would benefit most from a PET/CT seem to be those with multiple and bilobar tumors, who develop liver recurrence in follow-up after RFA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Find the latest articles, discoveries, and news in related topics.

References

  1. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246:559–65; discussion 565–7.

    Article  PubMed  Google Scholar 

  2. Kierans AS, Elazzazi M, Braga L, Leonardou P, Gerber DA, Burke C, et al. Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol. 2010;194:523–9.

    Article  PubMed  Google Scholar 

  3. Foroutani A, Garland AM, Berber E, String A, Engle K, Ryan TL, et al. Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors. Arch Surg. 2000;135:933–8.

    Article  PubMed  CAS  Google Scholar 

  4. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–89.

    PubMed  CAS  Google Scholar 

  5. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104:2658–70.

    Article  PubMed  Google Scholar 

  6. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–47; discussion 447–50.

    Article  PubMed  Google Scholar 

  7. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027–34; discussion 1035–6.

    Article  PubMed  Google Scholar 

  8. Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003;84:215–23.

    Article  PubMed  Google Scholar 

  9. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192–7.

    PubMed  Google Scholar 

  10. Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol. 2008;67:362–71.

    Article  PubMed  Google Scholar 

  11. Kuehl H, Stattaus J, Hertel S, Hunold P, Kaiser G, Bockisch A, et al. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours—a single-centre experience. Clin Oncol (R Coll Radiol). 2008;20:234–40.

    Article  CAS  Google Scholar 

  12. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80–7.

    Article  PubMed  Google Scholar 

  13. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358–64.

    Article  PubMed  Google Scholar 

  14. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg. 2010;145:340–5; discussion 345.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Tumor Ablation Program, Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA

    Dursun Ali Sahin MD, Orhan Agcaoglu MD, Celia Chretien CNS, Allan Siperstein MD & Eren Berber MD

Authors
  1. Dursun Ali Sahin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orhan Agcaoglu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Celia Chretien CNS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Allan Siperstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eren Berber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eren Berber MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahin, D.A., Agcaoglu, O., Chretien, C. et al. The Utility of PET/CT in the Management of Patients With Colorectal Liver Metastases Undergoing Laparascopic Radiofrequency Thermal Ablation. Ann Surg Oncol 19, 850–855 (2012). https://doi.org/10.1245/s10434-011-2059-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-2059-7

Keywords

Search

Navigation